Patterns of Response to Treatment and Further Treatment on Progression in Patients Receiving CDK4/6 Inhibitors (CDK4/6i) for ER+ve, HER2-ve Metastatic Breast Cancer (MBC)

Purpose: CDK4/6i in combination with endocrine treatment (ET) increases response rates and prolongs progression-free survival (PFS) in patients with ER+ve HER2-ve MBC when used in the first- or second-line setting. The patterns of response to treatment with CDK4/6i are not well characterised in the literature and treatment used at the point of progression is not standardised.

Source: Clinical Oncology - May 6, 2023 Category: Radiology Authors: R. Goh, A. Makris, A. Guppy, C. Westbury Source Type: research